Balance Sheet
Cash Flow Statement
Capital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

TScan Therapeutics (TCRX) Other financing activities (2021 - 2025)

TScan Therapeutics (TCRX) has disclosed Other financing activities for 3 consecutive years, with $75000.0 as the latest value for Q2 2025.

  • Quarterly Other financing activities changed N/A to $75000.0 in Q2 2025 from the year-ago period, while the trailing twelve-month figure was $200000.0 through Dec 2025, changed N/A year-over-year, with the annual reading at $200000.0 for FY2025, N/A changed from the prior year.
  • Other financing activities for Q2 2025 was $75000.0 at TScan Therapeutics, down from $125000.0 in the prior quarter.
  • The five-year high for Other financing activities was $748000.0 in Q2 2021, with the low at -$960000.0 in Q3 2021.
  • Average Other financing activities over 3 years is $74857.1, with a median of $125000.0 recorded in 2025.
  • Peak annual rise in Other financing activities hit 123.96% in 2022, while the deepest fall reached 123.96% in 2022.
  • Over 3 years, Other financing activities stood at -$960000.0 in 2021, then skyrocketed by 109.79% to $94000.0 in 2022, then decreased by 20.21% to $75000.0 in 2025.
  • According to Business Quant data, Other financing activities over the past three periods came in at $75000.0, $125000.0, and $94000.0 for Q2 2025, Q1 2025, and Q4 2022 respectively.